SCHEMBL6887688

SCHEMBL6887688

CCCC(C(C(=O)O)C(=O)O)N1C(=O)C(=Cc2ccc(OC(C)=O)cc2)SC1=S

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
PTPN1 P18031 6/20 0.57
MAPT P10636 3/20 0.52
CRHBP P24387 2/20 0.52
CRHR2 Q13324 2/20 0.52
ALDH1A1 P00352 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
BCL2 P10415 8/20 0.50
BCL2L2 Q92843 7/20 0.50
BAD Q92934 5/20 0.50
BCL2L1 Q07817 1/20 0.49
MCL1 Q07820 1/20 0.49
BAK1 Q16611 1/20 0.49
PLA2G1B P04054 1/20 0.48
POLB P06746 1/20 0.48
ATG4B Q9Y4P1 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6886503 0.87 PTPN1 (0.57) MEN1KMT2APTPN1MAPTBCL2
SCHEMBL6886589 0.87 PTPN1 (0.56) MEN1KMT2APTPN1MAPTCRHBP
SCHEMBL6885210 0.85 PTPN1 (0.61) MEN1KMT2APTPN1MAPTCRHBP
SCHEMBL6884215 0.85 PTPN1 (0.59) MEN1KMT2APTPN1MAPTALDH1A1
SCHEMBL6888396 0.83 MAPT (0.56) MEN1KMT2APTPN1MAPTCRHBP
SCHEMBL6879804 0.83 MAPT (0.57) MEN1KMT2APTPN1MAPTCRHBP
SCHEMBL6879801 0.83 MAPT (0.57) MEN1KMT2APTPN1MAPTCRHBP
SCHEMBL6887136 0.82 PTPN1 (0.55) MEN1KMT2APTPN1MAPTCRHBP
SCHEMBL6885437 0.81 HPGD (0.54) MEN1KMT2APTPN1MAPTCRHBP
SCHEMBL6885434 0.81 HPGD (0.54) MEN1KMT2APTPN1MAPTCRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6673816-B1 Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders Esswein, Angelika (DE) 2004-01-06 US disclosed
US-20030032813-A1 Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders ANGELIKA ESSWEIN, WOLFGANG SCHAEFER, AND KONRAD HONOLD 2003-02-13 US disclosed
EP-1117655-A1 RHODANINE CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS Esswein, Angelika (DE) 2001-07-25 EP disclosed
WO-2000018747-A1 RHODANINE CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS ROCHE DIAGNOSTICS GMBH (DE) 2000-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030032813-A1 Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders NR1H4, NR1D1, NR1I2 MEN1 838/4885KMT2A 1995/4885PTPN1 2479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.